On 26th July 2024, the European Commission has approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) that does not harbour sensitizing EGFR mutations, or ALK, ROS1, or RET genomic aberrations. Sugemalimab in combination with platinum-based chemotherapy becomes the world’s first anti-PD-L1 monoclonal antibody with statistically significant prolongation of overall survival for lung cancer patients in comparison to chemotherapy. The European Commission’s approval is also marking the first successful European approval of a China domestic anti-PD-L1 monoclonal antibody.
Ewopharma and CStone have entered into a strategic commercialization partnership for sugemalimab in Central & Eastern Europe and Switzerland on 27th May 2024.
Further information is available at Ewopharma and CStone enter into a Strategic Partnership for Sugemalimab in Central Eastern Europe and Switzerland